Personalized targeting of BCL2 family proteins overcomes acquired resistance to BRAF-MEK inhibitors in preclinical melanoma

Y. N. Vashisht Gopal, Evelyn de Groot, Kaley Loftin, Barbara Knighton, Debora Ledesma, Courtney Hudgens, Diana Shamsutdinova, Mehboob Ali, Zhenlin Ju, Min Xiao, Toshitha Kannan, Gregory Fontenot, Michael S. Nakazawa, Monzy Thomas, Khalida Wani, Clifford Stephan, Phyu P. Aung, Lawrence N. Kwong, Janos Roszik, Rehan Akbani, Andrew Kossenkov, Vito W. Rebecca, Ryan J. Sullivan, Meenhard Herlyn, Michael A. Davies · 2026

Read Personalized targeting of BCL2 family proteins overcomes acquired resistance to BRAF-MEK inhibitors in preclinical melanoma by Y. N. Vashisht Gopal, Evelyn de Groot, Kaley Loftin, Barbara Knighton, Debora Ledesma, Courtney Hudgens, Diana Shamsutdinova, Mehboob Ali, Zhenlin Ju, Min Xiao, Toshitha Kannan, Gregory Fontenot, Michael S. Nakazawa, Monzy Thomas, Khalida Wani, Clifford Stephan, Phyu P. Aung, Lawrence N. Kwong, Janos Roszik, Rehan Akbani, Andrew Kossenkov, Vito W. Rebecca, Ryan J. Sullivan, Meenhard Herlyn, Michael A. Davies (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13421458.txt.

Description

Y. N. Vashisht Gopal leads a large team testing, in a 2026 preclinical study, personalised drug combinations for melanoma that has stopped responding to BRAF and MEK inhibitors. No effective targeted therapy exists for this acquired resistance, and proteins of the BCL2 family, which block cell death, were suspected accomplices.

Using a large panel of patient-derived tumour grafts in mice, the team found that adding a BCL2 blocker to the standard pair shrank tumours in a subset. High starting BCL2 predicted success, while high MCL1 — another family member — predicted failure, confirmed by engineering MCL1 upward. Pairing an MCL1 blocker with the standard drugs overcame that resistance and softened the heart-toxicity markers linked to MCL1 blockade.

Catalog record

CREATORY. N. Vashisht Gopal, Evelyn de Groot, Kaley Loftin, Barbara Knighton, Debora Ledesma, Courtney Hudgens, Diana Shamsutdinova, Mehboob Ali, Zhenlin Ju, Min Xiao, Toshitha Kannan, Gregory Fontenot, Michael S. Nakazawa, Monzy Thomas, Khalida Wani, Clifford Stephan, Phyu P. Aung, Lawrence N. Kwong, Janos Roszik, Rehan Akbani, Andrew Kossenkov, Vito W. Rebecca, Ryan J. Sullivan, Meenhard Herlyn, Michael A. Davies
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE87847
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13421458

Browse the full library · About the Tower of Babel